LY2835219, a selective inhibitor of CDK4 and CDK6, inhibits growth in preclinical models of human cancer.

被引：8
|
作者：
Dempsey, Jack A. [1 ]
Chan, Edward M. [1 ]
Burke, Teresa F. [1 ]
Beckmann, Richard P. [1 ]
机构：
[1] Eli Lilly & Co, Indianapolis, IN 46285 USA
来源：
CANCER RESEARCH | 2013年 / 73卷 / 08期
关键词：
D O I：
10.1158/1538-7445.AM2013-LB-122
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LB122
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Clinical activity of LY2835219, a novel cell cycle inhibitor selective for CDK4 and CDK6, in patients with metastatic breast cancer
    Patnaik, Amita
    Rosen, Lee S.
    Tolaney, Sara M.
    Tolcher, Anthony W.
    Goldman, Jonathan W.
    Gandhi, Leena
    Papadopoulos, Kyriakos P.
    Beeram, Muralidhar
    Rasco, Drew W.
    Myrand, Scott P.
    Kulanthaivel, Palaniappan
    Li, Lily
    Frenzel, Martin
    Cronier, Damien M.
    Chan, Edward M.
    Flaherty, Keith T.
    Wen, Patrick Y.
    Shapiro, Geoffrey I.
    CANCER RESEARCH, 2014, 74 (19)
  • [2] Clinical activity of LY2835219, a novel cell cycle inhibitor selective for CDK4 and CDK6, in patients with non-small cell lung cancer.
    Goldman, Jonathan Wade
    Gandhi, Leena
    Patnaik, Amita
    Rosen, Lee S.
    Hilton, John Frederick
    Papadopoulos, Kyriakos P.
    Tolaney, Sara M.
    Beeram, Muralidhar
    Rasco, Drew Warren
    Myrand, Scott P.
    Beckmann, Richard P.
    Kulanthaivel, Palaniappan
    Frenzel, Martin
    Cronier, Damien
    Chan, Edward M.
    Flaherty, Keith
    Wen, Patrick Y.
    Tolcher, Anthony W.
    Shapiro, Geoffrey
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [3] A first-in-human phase I study of the CDK4/6 inhibitor, LY2835219, for patients with advanced cancer.
    Shapiro, Geoffrey
    Rosen, Lee S.
    Tolcher, Anthony W.
    Goldman, Jonathan Wade
    Gandhi, Leena
    Papadopoulos, Kyriakos P.
    Tolaney, Sara M.
    Beeram, Muralidhar
    Rasco, Drew Warren
    Kulanthaivel, Palaniappan
    Li, Qian
    Hu, Tianle
    Cronier, Damien
    Chan, Edward M.
    Flaherty, Keith
    Wen, Patrick Y.
    Patnaik, Amita
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [4] Clinical Activity of Abemaciclib (LY2835219), a Cell Cycle Inhibitor Selective for CDK4 and CDK6, in Patients with Relapsed or Refractory Mantle Cell Lymphoma
    Morschhauser, Franck
    Bouabdallah, Kamal
    Stilgenbauer, Stephan
    Thieblemont, Catherine
    Wolf, Martin
    de Guibert, Sophie
    Zettl, Florian
    Hahka-Kemppinen, Marjo
    Wang, David Xiaohui
    Brueck, Patrick
    Caldwell, Charles
    Beckmann, Richard
    Gelbert, Lawrence
    Cronier, Damien
    Lin, Ji
    Li, Lily
    Chan, Edward M.
    Pfreundschuh, Michael
    Wilhem, Martin
    Hess, Georg
    BLOOD, 2014, 124 (21)
  • [5] LY2835219, a novel cell cycle inhibitor selective for CDK4/6, in combination with fulvestrant for patients with hormone receptor positive (HR plus ) metastatic breast cancer.
    Patnaik, Amita
    Rosen, Lee S.
    Tolaney, Sara M.
    Tolcher, Anthony W.
    Goldman, Jonathan Wade
    Gandhi, Leena
    Papadopoulos, Kyriakos P.
    Beeram, Muralidhar
    Rasco, Drew Warren
    Myrand, Scott P.
    Kulanthaivel, Palaniappan
    Andrews, Joan M.
    Frenzel, Martin
    Cronier, Damien
    Chan, Edward M.
    Flaherty, Keith
    Wen, Patrick Y.
    Shapiro, Geoffrey
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [6] Combination of CDK4/6 inhibitor, LY2835219, and mTOR inhibitor to synergistically suppress the growth of head and neck squamous cell carcinoma
    Ahn, Myung-Ju
    Ku, Bo Mi
    Yi, Seong Yoon
    Koh, Jiae
    Bae, Yeon-Hee
    Sun, Jong-Mu
    Lee, Se-Hoon
    Ahn, Jin Seok
    Park, Keunchil
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [7] CDK4/6 inhibitor (LY2835219) exhibits potent anti-tumor activity in human lung cancer cell lines with intact retinoblastoma
    Goldman, J. W.
    Garon, E. B.
    Conklin, D.
    Wong, D. J. L.
    Wolf, B.
    Silveira, D. D.
    Kamranpour, N.
    Pitts, S.
    Finn, R. S.
    Slamon, D. J.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : 162 - 162
  • [8] Preclinical head-to-head comparison of CDK4/6 inhibitor activity toward CDK4 vs CDK6
    Delach, Scott
    Caponigro, Giordano
    CANCER RESEARCH, 2021, 81 (04)
  • [9] Targeting CDK4 and CDK6 in cancer
    Shom Goel
    Johann S. Bergholz
    Jean J. Zhao
    Nature Reviews Cancer, 2022, 22 : 356 - 372
  • [10] Targeting CDK4 and CDK6 in cancer
    Goel, Shom
    Bergholz, Johann S.
    Zhao, Jean J.
    NATURE REVIEWS CANCER, 2022, 22 (06) : 356 - 372
12345